parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.09 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in myonuclei	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 2870

ZNF423 in dopamine neurons, braak-0.51 (p 0.163) → -0.13 (p 0.739)receipt 2878
ZNF423 in astrocytes, braak+0.31 (p 0.416) → +0.06 (p 0.873)receipt 2877

receipt 2878: ZNF423 in dopamine neurons, braak

power: full sample -0.43 (p 0.072, n 18), 95% CI -0.75 to +0.04. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.43 (p 0.072, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.52 (p 0.028, n 18). not the mix.
skeptic: leave-one-out range -0.60 to -0.36, sign flips 0; without severely affected donors -0.43 (p 0.072, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ZNF423 in dopamine neurons.

case closed: nothing better to follow up.

receipt 2877: ZNF423 in astrocytes, braak

power: full sample +0.24 (p 0.346, n 18), 95% CI -0.26 to +0.63. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.23 (p 0.369, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.21 (p 0.398, n 18). could be the mix.
skeptic: leave-one-out range +0.12 to +0.37, sign flips 0; without severely affected donors +0.24 (p 0.346, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ZNF423 in astrocytes.

case closed: nothing better to follow up.

loading the receipts